Accelerating Therapeutic Discovery: ATX-Gx™ Human, Transgenic Platform
Webinar Overview
Ready to dramatically accelerate your therapeutic antibody discovery pipeline? In this presentation, Dr. John “Lippy” Lippincott shares how our ATX-Gx™ human, transgenic mouse platform can help:
- Accelerate antibody discovery: Learn how this platform, used by 100’s of biotechs and large pharma, can significantly speed up the identification of therapeutic antibody candidates against diverse targets.
- Improve your chances for success: Discover how the ATX-GKH have faster, more robust responses across all targets classes
- Reduce risk with a clinically validated platform: Gain access to insights that have already helped partners file 12 INDs since 2019 and declare 70+ program leads
Webinar sample above. To access the full video content, fill out the form below.
About the Speaker:
John Lippincott, PhD
Senior Vice President of
Therapeutic Discovery Strategies
Alloy Therapeutics
Dr. John “Lippy” Lippincott is Senior Vice President of Therapeutic Discovery Strategies at Alloy Discovery Services. He has over two decades of experience in the generation and characterization of antibodies from in vivo systems.
Prior to joining the deeply experienced team at Alloy, Lippy established and led the discovery group at Pfizer’s San Diego site where he was project leader for internal and external therapeutic discovery projects. After Pfizer he joined lgenica where he led the successful implementation of a novel in vivo discovery platform, created a high-throughput discovery system, and led other processes required for identifying lead therapeutic candidates. After his time at Igenica, he served in the roles of Vice President at various other discovery service companies.
Lippy received his PhD from Harvard University and did his postdoctoral research at the Genomics Institute of the Novartis Research Foundation in San Diego.
Ready to license the ATX-Gx™ Humanized Mouse Platform
